Gain Therapeutics Inc
GANX
Market Cap$59.22M
Close$
$0.43
79% downside
Current Fair Value
79% downsideOvervalued by 79% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $59.22 Million |
|---|---|
| Enterprise Value | $49.74 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.89 |
| Beta | 0.19 |
| Outstanding Shares | 27,132,588 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.74 |
|---|---|
| PEG | 55.55 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 767.53 |
| Enterprise Value to EBIT | -2.32 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Gain Therapeutics Inc
16 employeesGain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options fo...